Preeclampsia and intrauterine growth restriction (IUGR) are two of the most common adverse pregnancy outcomes, but their underlying causes are mostly unknown. Although multiple studies have investigated gene expression changes in these disorders, few studies have examined epigenetic changes. Analysis of the DNA methylation pattern associated with such pregnancies provides an alternative approach to identifying cellular changes involved in these disorders. We analyzed methylation of 1505 CpG sites associated with 807 genes in 26 placentas from early-onset preeclampsia (EOPET), late-onset preeclampsia, IUGR and control subjects using an Illumina GoldenGate Methylation panel. Thirty-four loci were hypomethylated (false discovery rate o10% and methylation difference 410%) in the early-onset preeclamptic placentas while no and only five differentially methylated loci were found in late-onset preeclamptic and IUGR placentas, respectively. Hypomethylation of 4 loci in EOPET was further confirmed by bisulfite pyrosequencing of 26 independent placental samples. The promoter of TIMP3 was confirmed to be significantly hypomethylated in EOPET placentas (P¼0.00001). Our results suggest that gene-specific hypomethylation may be a common phenomenon in EOPET placentas, and that TIMP3 could serve as a potential prenatal diagnostic marker for EOPET.
INTRODUCTION
Preeclampsia is one of the leading causes of maternal and fetal morbidity and mortality, and affects 5% of all pregnancies. 1, 2 It is characterized by high blood pressure in the mother and, frequently, growth deficiency in the fetus. Preeclampsia is heterogeneous in etiology and can be further subclassified into early-onset (o34 weeks) and late-onset (Z34 weeks). 3 Intrauterine growth restriction (IUGR), even in the absence of preeclampsia, may show similar placental pathology (shallow invasion and remodelling of maternal vessels) and is also associated with significantly increased perinatal morbidity and mortality, as well as with disorders arising later in life. 4, 5 Over decades, little progress has been made in the treatment and management of these disorders because they can only be diagnosed after full-blown manifestation of the condition is developed, by which time, treatment options are limited. Therefore, the identification of biomarkers that could be used to diagnose abnormal outcomes during early pregnancy would be a major step forward in antenatal care.
Although the exact cause is still unknown, epigenetic features are implicated in the pathogenesis of preeclampsia. Mutations in STOX1 were identified in some unique familial cases of preeclampsia with apparent maternal-only transmission of susceptibility. 6 In addition, deficiency of the imprinted Cdkn1c gene in mice can lead to hypertension and proteinuria during pregnancy, 7 further implicating the role of imprinted genes in the development of preeclampsia. Epigenetic alterations of non-imprinted genes have also been suggested to be involved. For example, the SERPINA3 promoter was found to be hypomethylated in preeclampsia-associated placenta, 8 suggesting that the epigenetic alteration of this gene may be associated with reduced trophoblastic invasion and implicating this change as a potential biomarker for preeclampsia.
Many studies have investigated the gene expression profile in human placentas with preeclampsia and IUGR using genomic array technology. [9] [10] [11] However, many factors may cause short-lived temporal changes in gene expression [12] [13] [14] and, furthermore, placental RNA can degrade during parturition and rapidly after delivery of the placenta, 15 making it difficult to obtain useful samples. DNA methylation is generally more stable and provides an alternative marker for underlying processes in the cell. In a previous study, we focused on the identification of highly variable 'epipolymorphisms' in the placenta. We then showed an association of one such epipolymorphism in TUSC3 with late-onset preeclampsia (LOPET), suggesting a role of altered DNA methylation in adverse pregnancy outcomes. 16 In this study, we use the microarray data set to compare the patterns of DNA methylation in placental samples from pregnancies with and without preeclampsia and IUGR to search for potential biomarkers for these disorders.
MATERIALS AND METHODS

Sample collection
Fifty-seven placentas with or without associated preeclampsia and/or IUGR were collected from Vancouver BC Children's and Women's Hospital with informed consent from individuals, as was approved by the ethics committees of the University of British Columbia and the Children's and Women's Health Centre of British Columbia. Some data on these placentas have been previously published including analysis of trisomy in the placenta, 17 analysis of altered imprinting for 11p15.5 imprinting control regions 18 and an investigation of methylation variability in the placenta. 16 Clinical information was collected on prenatal findings, pregnancy complications and birth parameters. Preeclampsia was defined as at least two of the following: (1) hypertension (systolic blood pressure Z140 mm Hg and/or diastolic blood pressure Z90 mm Hg, twice, 44 h apart) after 20 weeks, and proteinuria defined as Z0.3g/day or Z2+ dipstick proteinuria after 20 weeks, (2) non-hypertensive and non-proteinuric HELLP syndrome, using Sibai's criteria 19 or (3) an isolated eclamptic seizure without preceding hypertension or proteinuria, using the British Eclampsia Survey Team criteria to define eclampsia. 20 The preeclamptic placentas were subclassified into early-onset preeclampsia (EOPET) (onset before 34 weeks) and LOPET (onset at or after 34 weeks). 3 IUGR was defined as either (1) birth weight less than third percentile for gender and gestational age using Canadian charts 21 or (2) birth weight less than tenth percentile with either: (a) persistent uterine artery notching at 22+0 to 24+6 weeks gestation, (b) absent or reversed end diastolic velocity on umbilical artery Doppler and/or (c) oligohydramnios (amniotic fluid index o50 mm). All the LOPET and IUGR cases, 6 of the 17 EOPET cases, and 19 of the 32 controls overlap those used in our previous study of placental methylation variability. 16 Detailed clinical information is provided in Supplementary Table 3 . Although clinical details such as blood pressure and urine protein level were not always available in our controls, we excluded any cases reported as having hypertension or low birth weight.
Fragments of B1 cm 3 were dissected from the fetal side of each placenta and DNA was extracted immediately after collection. Total RNA was extracted from five control placentas with two sites sampled from each placenta using RNeasy kit (Qiagen, Valencia, CA, USA) according to manufacturer's instructions. Peripheral blood samples from normal individuals and fetal tissue biopsies (brain, kidney and lung) from abortuses were obtained with review board approval and were anonymous to individual identifiers.
Illumina microarray
DNA samples from 26 placentas were used for the DNA methylation array analysis. Samples were classified into three groups (EOPET, LOPET and IUGR) with their gestation-matched controls (Table 1 ). In addition, DNA samples from five additional control placentas with two sites dissected from each placenta were used to test for intra-individual DNA methylation variation. DNA samples extracted from blood of five normal female individuals and fetal tissues (brain, kidney and lung) from three abortuses were used to assess the tissue-specificity of methylation in the candidate loci. In all, 500 ng of genomic DNA was bisulfite modified using the EZ DNA Methylation Kit (Zymo Research, Orange, CA, USA) according to the manufacturer's instructions. After bisulfite treatment, DNA samples were subjected to the Illumina GoldenGate Methylation Cancer Panel I array-based assay, which contains 1505 probes targeting 807 genes, using Illumina-supplied reagents and conditions. Bisulfite converted DNA was mixed with allele-specific oligonucleotides in the assay, which target either the unmethylated cytosine (U) or methylated cytosine (C). A b-value of 0 to 1 was reported for each CpG site, which is related to the percentage of methylation, from 0 to 100%. b-values were calculated by subtracting background with the use of negative controls on the array and taking the ratio of the methylated signal intensity to the sum of both methylated and unmethylated signals. As a quality control step for Illumina array data analysis, we eliminated the probes with detection P-value 40.05 in any sample. To control for the possibility of methylation differences arising because of gender bias, we excluded all the probes on the X chromosome from our analysis. Differentially methylated loci between groups were identified based on the average DNA methylation level difference (D b) comparison and significance analysis of microarrays (SAM). 22 DNA methylation and RNA expression of 10 placental sites from 5 normal term placentas were further assayed using the Illumina GoldenGate Methylation array and the Illumina Human Gene Expression array, respectively. Total RNA quality was verified and processed samples were hybridized to an eightwell microarray chip (HumanRef-8 v2). The BeadChip array was processed in the Centre for Molecular Medicine and Therapeutics BioAnalyzer Core Facility (Vancouver, BC, Canada). Output was analyzed using Illumina's BeadStudio software v3.2.7, 2007 (Illumina, San Diego, CA, USA).
Bisulfite pyrosequencing
Loci with absolute d b 410% and false discovery rate (FDR) o10% in SAM were considered candidates of interest. To validate the differentially methylated loci identified from the Illumina array, bisulfite pyrosequencing was carried out for a subset of the candidate loci. In addition to the 26 samples run on the Illumina array, an independent set of 26 DNA samples from 13 EOPET and 13 control placentas were studied to validate the array findings. Pyrosequencing was performed on a Biotage Pyromark Q96 MD Pyrosequencer and the quantitative levels of methylation for each CpG dinucleotide were evaluated using Pyro Q-CpG software (Biotage, Uppsala, Sweden). All methylationunbiased PCR and sequencing primers were designed to cover the same CpG sites interrogated by the Illumina probes (Supplementary Table 1 ). Methylation analysis of LINE1 elements was performed according to manufacturer's instructions (Biotage), as this measurement is commonly used as an indirect measure of global methylation.
Statistical analysis
Data from bisulfite pyrosequencing were analyzed with two-tailed Student's t-test. Linear correlation was used to analyze the intra-individual methylation variation, the correlation between DNA methylation and gene expression, as well as the correlation between data obtained from Illumina array and bisulfite pyrosequencing assays.
RESULTS
Unsupervised hierarchical clustering was performed on the Illumina
GoldenGate methylation bead-array result from the 26 placental samples using the Illumina software and based on a distance measure of 1-r, where r is the Pearson correlation coefficient (Supplementary Figure 1) . There was no obvious clustering of EOPET, LOPET, IUGR and control placentas. However, there was a preferential clustering of placentas according to gender (Supplementary Figure 2A) , which is presumably caused by the inactivation of X chromosome in females (ie, higher methylation of X chromosome CpG islands in female than in male samples). After eliminating loci on the X chromosome from our analysis, the samples preferentially clustered according to their Figure 2B) . In particular, only 2 out of 14 control placentas did not cluster based on this classification. These results suggested that gender and gestational age of samples were potential biases for DNA methylation analysis.
To eliminate these potential biases in the search of differentially methylated loci between placentas with and without adverse pregnancy outcomes, all Illumina probes on the X chromosome were excluded from our study. Furthermore, cases and controls were compared separately for each gestational age-matched group (ie, three comparison groups: EOPET, LOPET and IUGR, with their corresponding gestational age-matched controls). Within these matched groups, there was no significant difference of gestational age or maternal age (Table 1) . Using a cut-off of o10% FDR from SAM, 192 loci were identified as being differentially methylated in EOPET as compared with controls, 16 loci in IUGR, but none in LOPET ( Figure 1 ). As differences of small magnitude are less likely to be meaningful, we only considered differences between the mean methylation of patient and control groups of at least 10% absolute magnitude difference. Of the 192 loci with o10% FDR for EOPET, 34 had a methylation difference 410% (D b 40.1 from Illumina array) and all of them were hypomethylated in EOPET compared with the controls (Table 2 ). Of the 16 loci identified by SAM for IUGR, five had 410% methylation difference between controls and IUGR, all of them were highly variable in methylation value consistent with being a methylation allelic polymorphismepipolymorphism as is commonly found in normal placentas. 16 To identify candidate sites at which methylation quantification could potentially be used for diagnostic purposes, it is important to select sites that are not greatly influenced by gestational age. Seven of the 34 candidate methylation changes associated with EOPET were significantly affected by gestational age as judged by comparing mean methylation in control placentas o34 gestational week as compared with controls Z34 gestational weeks (AATK_P519_R, ABCB4_P51_F, CDKN1C_P6_R, EMR3_P39_R, FRZB_E186_R, PSCA_E359_F, SH3BP2_P771_R; Student's t-test, Po0.05). From the remaining 27 loci, five sites (CAPG_E228_F, GLI2_E90_F, KRT13_P676_F, TIMP3_P690_R and MEST_E150_F) were selected for further validation by bisulfite pyrosequencing based on their magnitude of difference (GLI2, MEST and KRT13) and biological relevance to the preeclampsia development (CAPG, MEST and TIMP3). 23 Figure 1 Venn diagram summary of differentially methylated loci. Differentially methylated loci were defined by a false discovery rate (FDR) o10% as calculated by significance analysis of microarrays (indicated as 'SAM') and average DNA methylation difference 410% as represented by 'Delta Beta'. The number of differentially methylated loci is indicated in the overlapping area between circles. In all, 34 hypomethylated loci and 5 hypermethylated loci were identified in the EOPET group and IUGR group, respectively. *No differentially methylated locus was identified by SAM with FDR o10%. m: hypermethylated compared with the controls. k: hypomethylated compared with the controls. Bisulfite pyrosequencing validation of the five selected hypomethylated loci in EOPET showed that the Illumina array data correlate significantly with the pyrosequencing measurements for the same CpG site, as well as the mean of multiple sites in the pyrosequencing assays (Supplementary Table 2 ). To allow better representation of the methylation patterns in the associated regions, means of multiple CpG sites in pyrosequencing assays were used for all the comparisons. Therefore, an independent set of 26 placental samples, which consisted of 13 EOPET and 13 controls (gestational age was not significantly different between the two groups P¼0.49; clinical information of the samples can be found in Supplementary Table 3) , was analyzed by bisulfite pyrosequencing to confirm the differential methylation of the selected loci between EOPET and control placentas. All selected loci, except MEST (P¼0.60) showed significant hypomethylation in EOPET (P¼0.01 for CAPG, P¼0.03 for GLI2, P¼0.00003 for KRT13 and P¼0.00001 for TIMP3) (Figure 2) .
The most significant and largest absolute methylation difference (over 15%) was observed between EOPET and control at the TIMP3 locus. We tested the correlation in methylation values at this locus for two separately sampled sites from same placenta of five term control samples and these were well correlated with each other (R¼0.90; P¼0.038) (Supplementary Figure 3A) . We further studied the methylation values at 410 sampled sites from each of two term placentas. The SD of methylation values in two placentas were only 2.5 and 1.6% (Supplementary Figure 3B) , suggesting that there is little intraplacental variation of DNA methylation.
The feasibility of using placental DNA methylation for non-invasive prenatal diagnosis, requires differences to be present in comparison with maternal blood. From the Illumina array data, the TIMP3 locus was completely methylated in adult female blood and fetal tissues (99% methylated on average) with significant (P¼0.001) differential methylation compared with the placental samples (73% methylated on average), which is comparable to the methylation differences observed for SERPINB5 (Figure 3 ), a marker that was previously suggested feasible for non-invasive prenatal diagnosis. 26 Finally, we studied the relationship between the promoter DNA methylation and mRNA expression of the candidate genes in a subset of five term control placenta (two sampled sites each) that had been analyzed on the Illumina expression array. From the Illumina array data, we found that the DNA methylation of the TIMP3 locus was inversely correlated with its gene expression (R¼À0.72; P¼0.019), while none of the other three genes were significantly correlated based on this small sample size (N¼10 samples) (Supplementary Figure 4) .
DISCUSSION
In spite of the many suggestions that epigenetic changes might be involved in adverse pregnancy outcomes, 6, 8, 27 no genome-wide study has searched for epigenetic abnormalities in preeclampsia and IUGR. In this study, we profiled the DNA methylation of placentas from preeclampsia and IUGR pregnancies and their control counterparts using Illumina GoldenGate Methylation Cancer panel I array. Although the array mainly targets cancer-related genes, the pseudomalignant nature of the placenta makes it suitable for this study. 28 Among the 1505 CpG loci targeted by the array, 34 loci were identified as hypomethylated in EOPET but none was differentially methylated in LOPET. The different epigenetic profiles in EOPET and LOPET placentas support the hypothesis that the two forms of preeclampsia are caused by different mechanisms. 29, 30 EOPET, which is often associated with IUGR, is a severe form of preeclampsia (76% of our cases were associated with IUGR). It is suggested to be initiated by abnormal placentation, caused by reduced perfusion with increased apoptosis of trophoblasts. 2, 30, 31 In contrast, LOPET, which is considered to be a maternal syndrome, is a mild form of preeclampsia. It is usually associated with normal placental development and a predisposed maternal constitution, such as hypertension or diabetes. 2 Epigenetic change may have a role in EOPET by altering gene expression and, as a consequence, normal placental development. Epigenetic changes may also result from hypoxic conditions associated with preeclampsia or an altered trophoblast composition in these placentas. Hypomethylation was found in many gene promoter regions in EOPET, but there was no difference in the global DNA methylation level as indirectly assessed by methylation at the LINE1 repeat sequence compared with other groups of placentas (data not shown). As LINE1 methylation is a measure of global methylation, these results imply that CpG hypomethylation observed is a genespecific effect. Interestingly, many of the associated genes, such as the imprinted gene CDKN1C, are known to be important for normal placentation. 32 To control for maternal and gestational age factors, the sample size used for array profiling in this study is small (8 to 10 samples per group). The small sample size likely explains why we do not find an association between polymorphic DNA methylation of TUSC3 and LOPET as we did in a previous investigation of over 100 placentas (P¼0.02). 16 This latter study was focused on the identification of epipolymorphisms and did not involve the statistical comparison of all methylation sites between groups, as was conducted for this study.
Recently, we reported a reduction of methylation at the H19/IGF2 imprinting control region in IUGR-associated placentas, but we did not find altered methylation at CDKN1C or other imprinted genes in IUGR and/or preeclampsia. 18 The discrepancy can be attributed to the different ways of grouping samples, because we divided preeclampsia cases into PET and PET+IUGR previously without considering the effect of gestational changes on DNA methylation. Global changes of gene expression have been previously reported in association with gestational age. 33 Our current findings suggest this is important also in regard to DNA methylation. Thus, the gestational age-dependent profile is important to evaluate and control for when considering any methylation change identified as a potential biomarker. This is particularly important in the study of preeclampsia as such pregnancies tend to be delivered early and comparisons with term births may be inappropriate.
The DNA methylation differences of CpGs in CAPG, GLI2, KRT13 and TIMP3 were confirmed in an independent set of 26 placentas with EOPET and gestational age-matched control pregnancies. Among these four genes, TIMP3 had the largest difference in DNA methylation level with an over 15% reduction in EOPET compared with control placentas. A previous study showed that TIMP3 gene expression can be regulated by promoter DNA methylation in the placental tissues. 34 Although our assays target CpG sites upstream of the CpG island where previous groups analyzed (Figure 2d) , we also found a significant inverse correlation between its DNA methylation and gene expression in placentas. Therefore, hypomethylation of the TIMP3 promoter may alter its gene expression in EOPET.
TIMP3 is a family member of the matrix metalloproteinase inhibitors, which have an important function in regulating a wide range of physiological processes such as cell growth, invasion, migration transformation and apoptosis. This gene is highly expressed in placenta and suggested to be important for implantation and decidualization by regulating trophoblast invasion. 35, 36 Elevated expression of many TIMPs, including TIMP3, has been reported in preeclamptic placentas. 37, 38 The hypomethylation of the TIMP3 promoter found in this study may increase TIMP3 expression and, in turn, reduce the invasiveness of trophoblast during placental development, which leads to placental hypoperfusion in EOPET. Intriguingly, hypermethylation of the TIMP3 promoter has been reported in choriocarcinoma and hydatidiform mole, conditions that have increased trophoblast invasiveness, 34, 39 which further supports the inverse relationship between TIMP3 promoter methylation and trophoblast invasiveness. It has also been shown that TIMP3 could inhibit angiogenesis by blocking the vascular endothelial growth factor from binding its receptor, 25 a well-known defect that is found in the trophoblast of preeclamptic pregnancies. 40 Although the cause of the epigenetic modification is unknown, it may be related to the hypoxic environment of the cells. 41, 42 Intriguingly, TIMP3 expression was increased in the firsttrimester trophoblasts on hypoxic treatment. 43 This implies that the increased expression of TIMP3 under hypoxic condition, a hallmark in preeclamptic trophoblast, may be mediated by the epigenetic alteration on its promoter.
Early detection of preeclampsia is necessary for effective treatment. We identified several genes with hypomethylation in their promoter regions. In particular, the significant reduction of DNA methylation in TIMP3 promoter of EOPET placentas could be useful as a biomarker for the disorder. Importantly, this site showed no significant change of DNA methylation by gestational age and there was a good intraplacental correlation in DNA methylation values. If further study shows that this methylation change is also conserved earlier in pregnancy, then measuring the DNA methylation level of TIMP3 in chorionic villus sampling (CVS) from pregnant women could reflect subsequent risk for EOPET.
Recent advances in measuring circulating fetal DNA from maternal plasma opens up an additional approach for non-invasive prenatal diagnosis. 44 This strategy takes advantage of the fact that during pregnancy, 3 to 6% of cell-free DNA in maternal blood plasma is Figure 3 Comparison of DNA methylation levels of TIMP3 and SERPINB5 between placentas, blood and fetal tissues. Both (a) TIMP3 and (b) SERPINB5 show lower methylation level in control placentas (five cases) than fetal brain (two cases), kidney (three cases), lung (three cases) and female blood (five cases). b-value of 0 to 1 represents the relative percentage of methylation from 0 to 100%.
derived from the placenta. 44 Therefore, one can detect abnormalities in the fetal DNA directly from the maternal blood without going through invasive methods such as amniocentesis and CVS. It has been shown that there is an over fivefold increase in circulating fetal DNA in the maternal plasma of preeclamptic pregnancies compared with their control counterparts as estimated by measuring the placentalspecific unmethylated SERPINB5 DNA fragments. 26 However, SERPINB5 is not differentially methylated between normal and preeclamptic placentas. The same extent of increase in circulating fetal DNA can also be found in preeclamptic maternal plasma by measuring SRY, 45 suggesting that SERPINB5 is not a specific marker for preeclampsia. As TIMP3 is significantly hypomethylated in EOPET placentas the detection of an increased level of unmethylated TIMP3 cell-free DNA in the maternal plasma could provide increased sensitivity for the non-invasive screening of pregnancies for EOPET. Importantly, it possesses the same characteristics as SERPINB5 for being a potential universal non-invasive prenatal diagnostic marker: its methylation is specifically reduced in placenta but it is completely methylated in other tissues, including blood samples. SERPINA3, another gene in the SERPIN family, has been reported to be hypomethylated in severe preeclampsia, but the extent of methylation and its potential for being a clinical marker have not been examined thoroughly. 8 We suggest, therefore, that the level of unmethylated TIMP3 DNA in maternal plasma could be a useful biomarker for early detection of severe preeclampsia. In summary, we report the application of DNA methylation analysis to the elucidation of abnormal placental development associated with preeclampsia. Although DNA methylation at critical sites can reflect the availability of a gene for transcription, which may lead to altered expression depending on other regulatory factors present, it has a number of advantages over expression studies. First, it may be more resistant to the transient changes in gene expression associated with labor and delivery, [12] [13] [14] as well as the effects of placental storage before sample processing. 15 Although we did in this case observe an inverse association between TIMP3 methylation and expression, expression studies at term may not always reflect that which occurred during relevant periods of development. Second, the trend to hypomethylation of a variety of genes in EOPET suggests that loss of methylation may generally be involved in the response to hypoxia. Finally, DNA methylation differences provide an alternative approach for presymptomatic diagnosis of at risk pregnancies.
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